Key result
First Nations peoples with CHD receive similar secondary prevention medications compared to non-indigenous Australians.
Why the study?
Coronary heart disease is the primary cause of mortality in Australia and the largest contributor to the gap in cardiovascular disease deaths between First Nations people and non-indigenous Australians.
Do First Nations people with coronary heart disease receive similar secondary prevention medications and achieve similar clinical targets compared to non-indigenous Australians in primary care?
Cohort (n=50,088)
Yes
Do First Nations people with coronary heart disease receive similar secondary prevention medications and achieve similar clinical targets compared to non-indigenous Australians in primary care?
Odds Ratio: 0.9 (95% CI 0.8–1.1)
p-value: p=0.28
While First Nations people with CHD in active primary care receive similar rates of secondary prevention medications compared to non-indigenous Australians, they experience significantly worse achievement of metabolic targets such as HDL-C, triglycerides, and HbA1c.
No takes yet. Share an insight, caveat, or question.
Similar medication receipt does not ensure target achievement; leaves open disparities in adherence or intensification for First Nations CHD patients.
Wing‐Lun et al. (2025) conducted a cohort in Coronary heart disease (CHD) (n=50,088). Aboriginal and Torres Strait Islander (First Nations) status vs. Non-indigenous Australians was evaluated on Statin prescription (aOR 0.9, 95% CI 0.8-1.1, p=0.28). First Nations peoples with CHD received similar secondary prevention medications, including statins (aOR 0.9; 95% CI 0.8-1.1; P=0.28), compared to non-indigenous Australians.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: